πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 9 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10702473

Liposome formulation for delivery of Wnt signal pathway inhibitor

Curegenix, Inc. Β· Granted Tue Jul 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10660889

Compounds for treatment of cancer

Curegenix, Inc. Β· Granted Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10285988

Compounds for treatment of fibrosis diseases

Curegenix, Inc. Β· Granted Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10238652

Compounds for treatment of cancer

Curegenix, Inc. Β· Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10087181

Compound as WNT signaling inhibitor, composition, and use thereof

Curegenix, Inc. Β· Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9744169

Compounds for treatment of fibrosis diseases

Curegenix, Inc. Β· Granted Tue Aug 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9713612

Compounds for treatment of cancer

Curegenix, Inc. Β· Granted Tue Jul 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9556144

Compound as WNT signaling inhibitor, composition, and use thereof

Curegenix, Inc. Β· Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8785442

Compound as antagonist of lysophosphatidic acid receptor, composition, and use thereof

Curegenix, Inc. Β· Granted Tue Jul 22 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted